Lido Advisors LLC Has $4.31 Million Stock Position in Lantheus Holdings, Inc. $LNTH

Lido Advisors LLC cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 8.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 56,855 shares of the medical equipment provider’s stock after selling 5,350 shares during the period. Lido Advisors LLC’s holdings in Lantheus were worth $4,312,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. M&T Bank Corp acquired a new position in shares of Lantheus during the 4th quarter worth $370,950,000. Farallon Capital Management LLC boosted its stake in Lantheus by 56.1% in the fourth quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after buying an additional 1,950,252 shares in the last quarter. Norges Bank acquired a new stake in Lantheus in the fourth quarter valued at about $76,197,000. Freestone Grove Partners LP grew its position in Lantheus by 4,114.8% in the fourth quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock valued at $40,497,000 after acquiring an additional 594,088 shares during the last quarter. Finally, Summit Street Capital Management LLC bought a new position in Lantheus in the fourth quarter valued at about $26,997,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Ratings Changes

LNTH has been the subject of a number of research reports. B. Riley Financial increased their target price on shares of Lantheus from $97.00 to $129.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a report on Tuesday, May 26th. The Goldman Sachs Group reiterated a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a research report on Thursday, May 7th. Truist Financial increased their price objective on shares of Lantheus from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Finally, Citizens Jmp restated a “market outperform” rating and issued a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $110.43.

Lantheus Trading Up 1.1%

Shares of LNTH stock opened at $104.82 on Friday. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.86. The stock’s fifty day simple moving average is $103.36 and its 200 day simple moving average is $85.56. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $6.82 billion, a P/E ratio of 25.26 and a beta of -0.06.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same period last year, the company earned $1.53 earnings per share. The business’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 4.5 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.